288 related articles for article (PubMed ID: 22193235)
1. Soluble klotho and autosomal dominant polycystic kidney disease.
Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease.
Akiyama K; Mochizuki T; Kataoka H; Tsuchiya K; Nitta K
Nephrology (Carlton); 2017 Nov; 22(11):848-853. PubMed ID: 27450645
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
4. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
[TBL] [Abstract][Full Text] [Related]
5. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
[TBL] [Abstract][Full Text] [Related]
6. A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.
Kanai T; Shiizaki K; Betsui H; Aoyagi J; Yamagata T
CEN Case Rep; 2018 Nov; 7(2):259-263. PubMed ID: 29767399
[TBL] [Abstract][Full Text] [Related]
7. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
8. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
[TBL] [Abstract][Full Text] [Related]
9. Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease.
De Rechter S; Bacchetta J; Godefroid N; Dubourg L; Cochat P; Maquet J; Raes A; De Schepper J; Vermeersch P; Van Dyck M; Levtchenko E; D'Haese P; Evenepoel P; Mekahli D
J Clin Endocrinol Metab; 2017 Nov; 102(11):4210-4217. PubMed ID: 29092060
[TBL] [Abstract][Full Text] [Related]
10. Tubular phosphate transport: a comparison between different methods of urine sample collection in FGF23-dependent hypophosphatemic syndromes.
Arcidiacono GP; Camozzi V; Zaninotto M; Tripepi G; Fusaro M; Torres MO; Zanchetta F; Cannito M; Cecchinato A; Diogo M; Peleg Falb M; Plebani M; Simioni P; Sella S; Giannini S
Clin Chem Lab Med; 2024 May; 62(6):1126-1132. PubMed ID: 38295343
[TBL] [Abstract][Full Text] [Related]
11. Mediation of the relationship between proteinuria and serum phosphate: Insight from the KNOW-CKD study.
Jung JY; Ro H; Chang JH; Kim AJ; Lee HH; Han SH; Yoo TH; Lee KB; Kim YH; Kim SW; Park SK; Chae DW; Oh KH; Ahn C; Chung W
PLoS One; 2020; 15(6):e0235077. PubMed ID: 32569271
[TBL] [Abstract][Full Text] [Related]
12. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
Bienaimé F; Ambolet A; Aussilhou B; Brazier F; Fouchard M; Viau A; Barre P; Tissier AM; Correas JM; Paradis V; Terzi F; Friedlander G; Knebelmann B; Joly D; Prié D
J Clin Endocrinol Metab; 2018 Jun; 103(6):2319-2328. PubMed ID: 29618028
[TBL] [Abstract][Full Text] [Related]
14. Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients.
Ozeki M; Fujita S; Kizawa S; Morita H; Sohmiya K; Hoshiga M; Ishizaka N
BMC Nephrol; 2014 Sep; 15():147. PubMed ID: 25200959
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
[TBL] [Abstract][Full Text] [Related]
17. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
Giralt M; Chocron S; Ferrer R; Ariceta G
Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
Phelps KR; Mason DL
Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
[TBL] [Abstract][Full Text] [Related]
19. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
[TBL] [Abstract][Full Text] [Related]
20. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
